ANIMAL HEALTH NEWS-September

Vetoquinol reported first-half 2024 sales of EUR 264 million, a 3% increase, with net income down 26%. Around 50% of European veterinary drug registrations are generics, as discussed during Access VetMed’s CEOs Meeting in Bucharest. MSD Argentina focuses on technology and growth in companion animals, while Dechra Espa?a will host a feline hypertension webinar. Elanco received FDA approval for Zenrelia, a JAK inhibitor for dogs, and Zoetis will introduce its AI-powered Vetscan OptiCell analyzer. Boehringer Ingelheim showcased innovations in feline medicine at Cat in Rio, while Hill’s Pet Nutrition expanded its Science Diet line. Mexico City will launch a sustainable food lab at UNAM, and Royal Canin will sponsor the Expo Gatos in Brazil. Ouro Fino reported a 97.8% increase in adjusted net profit, and Syntec is leading veterinary innovation with new medications. Nestlé Purina granted $1 million to UC Davis, and Medgene will test vaccines for H5N1. Trupanion launched in Germany and Switzerland, Ceva began production of an autogenous vaccine for aMPV and presented a foot-and-mouth vaccine dossier in Argentina. Finally, Virbac partnered with APOP to tackle pet obesity in the US. #animalhealth #business #veterinary #industry #regulatoryaffairs #launches #sales

?? Vetoquinol reported results for the first half of 2024. Sales were EUR 264 million ($292 million), up 3% on a reported basis. Net income amounted to EUR 24 million ($26.6 million), a decline of 26%. (company website).

?? Around 50% of all veterinary drug registrations in Europe are generics. Access VetMed, the voice of generic veterinary medicines in Europe, held its Annual CEOs Meeting on September 12-13 in Bucharest, Romania. The event brought together more than 60 CEOs and staff from partner companies such as Calier, Dechra, Alivira - Laboratorios Karizoo, Labiana, Livisto, and Maymo (Grupo Zendal), among others. The industry is actively investing in product development, including those aimed at minor species, and in R&D to improve formulations and features that benefit both prescribers and users. (animalshealth.es, Sept. 17th).

?? MSD Argentina is betting on technology and is proud to have one of the most complete portfolios for all species in the country. Fabiano Hideto Ikejiri (CEO) arrived in Argentina in mid-2023 to take charge of MSD's Animal Health division. The subsidiary continues to foresee strong growth in the companion animal sector, while also focusing on traceability and prevention for production animals. (motivar.com.ar, Sept).

?? Dechra Spain will have Marta Planellas organize a webinar on feline hypertension. The event will take place on October 1 at 14:00h and will feature the prominent participation of Dr. Marta Planellas, a renowned veterinarian. Aimed at clinical veterinarians looking to improve their knowledge of hypertension in cats, attendees will learn about best practices in diagnosing, treating, and monitoring this condition, as well as discovering the latest advances in this field. (diarioveterinario.com, Sept. 20th).

?? Elanco Animal Health Incorporated announced the FDA has approved Zenrelia, a once-daily oral JAK inhibitor for controlling pruritus (itching) associated with allergic dermatitis and controlling atopic dermatitis in dogs at least 12 months of age. Orders are expected to begin shipping in the coming days. (company press release).

?? Zoetis Inc. announced plans to unveil its new hematology analyzer Vetscan OptiCell, a cartridge-based, AI-powered diagnostic tool that provides advanced Complete Blood Count (CBC) analysis. The analyzer will be introduced to the US market later this year. (prnewswire).

?? Boehringer Ingelheim do Brasil participated in Cat in Rio, an event held in Rio de Janeiro from August 22 to 24, showcasing important innovations in Feline Medicine. The company presented products such as Rabisin, a rabies vaccine, Frontline, a parasiticide for cats, and Stomorgyl, which treats oral conditions. Boehringer Ingelheim reinforced its commitment to offering new treatment options and innovation, reaffirming its satisfaction in participating once again in this prominent event in the sector. (Caesegatos.com.br, Sept).

?? Hill's Pet Nutrition announced it has expanded its Science Diet line with new Puppy and Kitten Sensitive Stomach & Skin foods. The new recipes are highly digestible with prebiotic fibers that promote healthy skin and coat and improve stool quality for easier poop pickup. (prnewswire).

?? Mexico City will have its first sustainable food lab at UNAM's Faculty of Veterinary Medicine. This lab will measure the composition of agricultural products and the pollution they generate in their production (carbon and water footprints); genomic analyses will also be conducted. A group of around 300 researchers from the National Autonomous University of Mexico (UNAM) has already expressed interest in participating in the National Sustainable Food Laboratory (LASOS), now in its initial creation stage and part of the Food Sustainability Laboratories Network (Red LABSA) projects. (diarioveterinario.com, Sept. 17th).

?? Royal Canin do Brasil, a specialist in Health Through Nutrition for cats and dogs, will be present at this year's second edition of Expo Gatos, one of the largest feline exhibitions in the country. Organized by Amacoon (Maine Coon Breed Association in Brazil), the event is officially sponsored by Royal Canin and will take place on September 21 and 22 at Casa Leone, located in the Historical Center of Santos (SP). The event is open to the public and offers cat lovers the opportunity to see some of the rarest and most exotic cat breeds in the world. Among the most anticipated is the Maine Coon, one of the oldest breeds in North America, with males weighing over 10 kilograms and females up to seven kilograms. (caesegatos.com.br, 17th of Sept.).

?? Ouro Fino Saúde Animal's adjusted net profit reached R$ 15.3 million in the second quarter of this year, an increase of 97.8% compared to the same period the previous year. Revenue fell by 6.3% to R$ 217.2 million. (globorural.globo.com, August).

?? Syntec do Brasil is transforming veterinary care with new medicines and a focus on innovation. The company remains attentive to market trends and plans to continue launching products that support animal treatment and welfare. Syntec, focused on developing innovative solutions, has directly contributed to recent diagnostic advances by launching products aimed not only at treating patients but also making the process more practical and accessible for pet owners. The company works with palatable formulations and easy-to-administer tablets designed to suit each animal's specific weight, simplifying daily treatment. Among Syntec's most recent launches are Isofluorane, the only veterinary inhalation anesthetic available on the market, offering greater safety during surgical procedures. Another innovative product is Syrox, a non-steroidal anti-inflammatory COX2 inhibitor used to control acute pain and inflammation, which presents a lower risk of side effects and is easy to administer. Additionally, the company launched Trilostec, a trilostane-based medication for treating hyperadrenocorticism, with bisected tablets that facilitate prescribing and ensure more precise dosing. (Caesegatos.com.br, Sept).

?? Nestlé Purina PetCare announced a grant of nearly $1 million over 5 years to support the University of California, Davis School of Veterinary Medicine's G.V. Ling Urinary Stone Analysis Laboratory (USAL). It will allow companion animal veterinarians to provide free urinary stone analysis results to their patients. (prnewswire).

?? Medgene announced it has responded to notice from the USDA Center for Veterinary Biologics (CVB) on testing vaccines to address H5N1 incidence in dairy cattle, and will test its rapid-response vaccine technology in a dairy cattle study. Separately, Medgene announced a partnership with Iowa State University to develop sheep and goat vaccines, funded by a two-year grant from the USDA Animal & Plant Health Inspection Service (APHIS) National Animal Disease Preparedness Response Program. (company press release).

?? Trupanion, Inc. announced the official launch of its Trupanion product in Germany and Switzerland. The launch follows the company’s expansion to Continental Europe in 2022 with the acquisition of pet insurance companies with expertise in the region. Trupanion policies in Germany and Switzerland will be administered and managed by Trupanion’s local team in Europe, and the policies will be underwritten locally by third parties. (company press release).

?? Ceva Animal Health announced it has begun antigen production for an experimental autogenous vaccine to fight the emerging Avian Metapneumovirus (aMPV) disease, with a finished product expected to be available in about 8 weeks (pending the passing of quality control checks). Ceva received authorization from the Center for Veterinary Biologics to ship a Type B isolate to its autogenous production facility in July 2024; there are currently no commercially licensed vaccines available in the US. (thepoultrysite.com).

?? Ceva Animal Health Argentina presented the dossier to begin the registration process for a foot-and-mouth disease vaccine. In an interview with Motivar, Patricio Roan highlighted Ceva Animal Health’s reproduction portfolio, emphasizing Foli-Rec. Ceva ranks fifth globally in animal health revenues and second among multinational companies in Argentina, with strong participation not only in poultry but also in ruminants, companion animals, and swine, offering internationally recognized products. In Argentina, the company is expected to generate EUR 50 million in revenue, with the ruminant business being the second most important sector for Ceva in Latin America, following Brazil. (motivar.com.ar, Sept.)

?? Virbac announced its partnership with the Association for Pet Obesity Prevention (APOP) to help address the growing issue of pet obesity throughout the United States. APOP and Virbac will collaborate to create educational resources and tools for pet owners and veterinarians, detailing the importance of more tailored nutrition to help maintain pets’ metabolic health following spaying or neutering. (Petfood Processing).

?? Virbac reported a revenue increase of over 15% in the first half of 2024, with a net profit of EUR 94.7 million, up 26.2% compared to the same period last year. Total revenue reached EUR 702.9 million, a 16.1% increase at constant exchange rates and a 15.1% overall growth compared to EUR 610.5 million in 2023. This growth was partly driven by the integration of recently acquired companies, such as Globion in India and Sasaeah in Japan, which contributed 4.8 points to the total growth. Additionally, organic growth reached 11.3%, fueled by increased volumes and prices, despite a slowdown in inflation. (animalshealth.es, 16th of Sept.).

Please, subscribe ?? Subscribe on LinkedIn https://www.dhirubhai.net/build-relation/newsletter-follow?entityUrn=6862344212038328321

or follow us ?? BERNARDO OTERO Animal Health Leadership

CEO & Founder of NEXUS ANIMAL HEALTH